GATA3 Mutations Found in Breast Cancers May Be Associated with Aberrant Nuclear Localization, Reduced Transactivation and Cell Invasiveness

Hormones and Cancer

Volumn 4, Issue 3, 2013, Pages 123-139

  Gaynor, Katherine U ^a   Grigorieva, Irina V ^a   Allen, Michael D ^b   Esapa, Christopher T ^a,c   Head, Rosemary A ^a,c   Gopinath, Preethi ^b   Christie, Paul T ^a   Nesbit, M Andrew ^a   Jones, J Louise ^b   Thakker, Rajesh V ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c MRC MAMMALIAN GENETICS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 3;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SIZE; CELL INVASION; CELL PROLIFERATION; CELL STRAIN COS7; CONTROLLED STUDY; DNA BINDING; FRAMESHIFT MUTATION; GEL MOBILITY SHIFT ASSAY; GENE INSERTION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOMATIC MUTATION; TRANSACTIVATION; TUMOR INVASION;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; MCF-7 CELLS; MUTATION; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84877036815     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0138-x     Document Type: Article

References (60)

1. Simon MC (1995) Gotta have GATA. Nat Genet 11: 9-11.
2. Fox AH, Liew C, Holmes M, Kowalski K, Mackay J, Crossley M (1999) Transcriptional cofactors of the FOG family interact with GATA proteins by means of multiple zinc fingers. EMBO J 18: 2812-2822.
3. van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P, Vanderlinden G, Harding B et al (2000) GATA3 haplo-insufficiency causes human HDR syndrome. Nature 406: 419-422.
4. Nesbit MA, Bowl MR, Harding B, Ali A, Ayala A, Crowe C, Dobbie A et al (2004) Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome. J Biol Chem 279: 22624-22634.
5. Ali A, Christie PT, Grigorieva IV, Harding B, van Esch H, Ahmed SF, Bitner-Glindzicz M et al (2007) Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Hum Mol Genet 16: 265-275.
6. Gaynor KU, Grigorieva IV, Nesbit MA, Cranston T, Gomes T, Gortner L, Thakker RV (2009) A missense GATA3 mutation, Thr272Ile, causes the hypoparathyroidism, deafness, and renal dysplasia syndrome. J Clin Endocrinol Metab 94: 3897-3904.
7. Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerod A et al (2004) Mutation of GATA3 in human breast tumors. Oncogene 23: 7669-7678.
8. Arnold JM, Choong DY, Thompson ER, Waddell N, Lindeman GJ, Visvader JE, Campbell IG, Chenevix-Trench G (2010) Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat 119: 491-496.
9. Chanock SJ, Burdett L, Yeager M, Llaca V, Langerod A, Presswalla S, Kaaresen R et al (2007) Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res 9: R5.
10. Stephens PJ, Tarpey PS, Davies H, van Loo P, Greenman C, Wedge DC, Nik-Zainal S et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404.
11. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409.
12. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, van Tine BA et al (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486: 353-360.
13. Tominaga N, Naoi Y, Shimazu K, Nakayama T, Maruyama N, Shimomura A, Kim S J, Tamaki Y, and Noguchi S (2012) Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. Ann Oncol 23(12): 3051-7.
14. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L et al (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9: 201-209.
15. Grigorieva IV, Mirczuk S, Gaynor KU, Nesbit MA, Grigorieva EF, Wei Q, Ali A et al (2010) Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. J Clin Invest 120: 2144-2155.
16. Ting CN, Olson MC, Barton KP, Leiden JM (1996) Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 384: 474-478.
17. Shiga K, Shiga C, Sasano H, Miyazaki S, Yamamoto T, Yamamoto M, Hayashi N, Nishihira T, Mori S (1993) Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression. Anticancer Res 13: 1293-1301.
18. Atayar C, Poppema S, Blokzijl T, Harms G, Boot M, van den Berg A (2005) Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am J Pathol 166: 127-134.
19. Gulbinas A, Berberat PO, Dambrauskas Z, Giese T, Giese N, Autschbach F, Kleeff J, Meuer S, Buchler MW, Friess H (2006) Aberrant gata-3 expression in human pancreatic cancer. J Histochem Cytochem 54: 161-169.
20. Hoch RV, Thompson DA, Baker RJ, Weigel RJ (1999) GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 84: 122-128.
21. Steenbergen RD, OudeEngberink VE, Kramer D, Schrijnemakers HF, Verheijen RH, Meijer CJ, Snijders PJ (2002) Down-regulation of GATA-3 expression during human papillomavirus-mediated immortalization and cervical carcinogenesis. Am J Pathol 160: 1945-1951.
22. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA (2010) Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 5: e10696.
23. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
24. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR et al (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
25. Allen MD, Vaziri R, Green M, Chelala C, Brentnall AR, Dreger S, Vallath S et al (2011) Clinical and functional significance of alpha9beta1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol 223: 646-658.
26. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
27. Krynska B, Del Valle L, Croul S, Gordon J, Katsetos CD, Carbone M, Giordano A, Khalili K (1999) Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc Natl Acad Sci U S A 96: 11519-11524.
28. Herrmann MG, Durtschi JD, Bromley LK, Wittwer CT, Voelkerding KV (2006) Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem 52: 494-503.
29. Jorde R, Schirmer H, Wilsgaard T, Joakimsen RM, Mathiesen EB, Njolstad I, Lochen ML et al (2012) Polymorphisms related to the serum 25-hydroxyvitamin d level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromso Study. PLoS One 7: e37295.
30. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL (2009) Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11: R24.
31. Thomas GJ, Lewis MP, Whawell SA, Russell A, Sheppard D, Hart IR, Speight PM, Marshall JF (2001) Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol 117: 67-73.
32. Esapa CT, Head RA, Jeyabalan J, Evans H, Hough TA, Cheeseman MT, McNally EG et al (2012) A mouse with an N-Ethyl-N-Nitrosourea (ENU) induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis. PLoS One 7: e43205.
33. Exome Variant Server, NHLBI Exome Sequencing Project (ESP) (2011) Seattle, WA (URL: http://evs. gs. washington. edu/EVS/). Accessed Sept 2012.
34. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F et al (2007) Clustal W and Clustal X version 2. 0. Bioinformatics 23: 2947-2948.
35. Pruitt KD, Tatusova T, Klimke W, Maglott DR (2009) NCBI reference sequences: current status, policy and new initiatives. Nucleic Acids Res 37: D32-D36.
36. Sigrist CJ, Cerutti L, de Castro E, Langendijk-Genevaux PS, Bulliard V, Bairoch A, Hulo N (2010) PROSITE, a protein domain database for functional characterization and annotation. Nucleic Acids Res 38: D161-D166.
37. DeLano WL (2002) The PyMOL molecular graphics system. Schrödinger, LLC, New York.
38. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R (2010) GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 285: 14042-14051.
39. Philips AS, Kwok JC, Chong BH (2007) Analysis of the signals and mechanisms mediating nuclear trafficking of GATA-4. Loss of DNA binding is associated with localization in intranuclear speckles. J Biol Chem 282: 24915-24927.
40. Yang Z, Gu L, Romeo PH, Bories D, Motohashi H, Yamamoto M, Engel JD (1994) Human GATA-3 trans-activation, DNA-binding, and nuclear localization activities are organized into distinct structural domains. Mol Cell Biol 14: 2201-2212.
41. Shoya Y, Kobayashi T, Koda T, Ikuta K, Kakinuma M, Kishi M (1998) Two proline-rich nuclear localization signals in the amino- and carboxyl-terminal regions of the Borna disease virus phosphoprotein. J Virol 72: 9755-9762.
42. Yang HY, Evans T (1992) Distinct roles for the two cGATA-1 finger domains. Mol Cell Biol 12: 4562-4570.
43. Bates DL, Chen Y, Kim G, Guo L, Chen L (2008) Crystal structures of multiple GATA zinc fingers bound to DNA reveal new insights into DNA recognition and self-association by GATA. J Mol Biol 381: 1292-1306.
44. Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K et al (2011) Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol 31: 4609-4622.
45. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118-132.
46. Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M, Ottewell PD (2012) Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Res 14: R86.
47. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, van der Saag PT, van der Burg B (1995) Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 6: 1151-1161.
48. Weiss MJ, Orkin SH (1995) GATA transcription factors: key regulators of hematopoiesis. Exp Hematol 23: 99-107.
49. Molkentin JD (2000) The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 275: 38949-38952.
50. Palmeri D, Malim MH (1999) Importin beta can mediate the nuclear import of an arginine-rich nuclear localization signal in the absence of importin alpha. Mol Cell Biol 19: 1218-1225.
51. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V (1990) Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 10: 6565-6577.
52. Rogozin IB, Pavlov YI (2003) Theoretical analysis of mutation hotspots and their DNA sequence context specificity. Mutat Res 544: 65-85.
53. Amos W (2010) Heterozygosity and mutation rate: evidence for an interaction and its implications: the potential for meiotic gene conversions to influence both mutation rate and distribution. Bioessays 32: 82-90.
54. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127: 1041-1055.
55. Manuylov NL, Smagulova FO, Tevosian SG (2007) Fog2 excision in mice leads to premature mammary gland involution and reduced Esr1 gene expression. Oncogene 26: 5204-5213.
56. Gibbons RJ, Wada T, Fisher CA, Malik N, Mitson MJ, Steensma DP, Fryer A, Goudie DR, Krantz ID, Traeger-Synodinos J (2008) Mutations in the chromatin-associated protein ATRX. Hum Mutat 29: 796-802.
57. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331: 1199-1203.
58. Kalderon D, Roberts BL, Richardson WD, Smith AE (1984) A short amino acid sequence able to specify nuclear location. Cell 39: 499-509.
59. Robbins J, Dilworth SM, Laskey RA, Dingwall C (1991) Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. Cell 64: 615-623.
60. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5): 403-410.